A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

NCT07661329 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open Angle Glaucoma (POAG)
Ocular Hypertension (OH)

Interventions

DRUG: Bimatoprost ophthalmic solution 0.01% YSBP
DRUG: bimatoprost ophthalmic solution 0.01% (Lumigan®)

Sponsor

YS Life Science Co., Ltd.